• Consensus Rating: Moderate Buy
  • Consensus Price Target: $12.20
  • Forecasted Upside: 682.05%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.56
▼ -0.05 (-3.11%)

This chart shows the closing price for RLYB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rallybio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RLYB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RLYB

Analyst Price Target is $12.20
▲ +682.05% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Rallybio in the last 3 months. The average price target is $12.20, with a high forecast of $18.00 and a low forecast of $8.00. The average price target represents a 682.05% upside from the last price of $1.56.

This chart shows the closing price for RLYB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 polled investment analysts is to moderate buy stock in Rallybio. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/2/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/31/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2024JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
5/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00Low
4/18/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$8.00Low
4/11/2024WedbushLower TargetOutperform ➝ Outperform$13.00 ➝ $11.00Low
3/13/2024HC WainwrightLower TargetBuy ➝ Buy$12.00 ➝ $9.00Low
3/13/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$8.00Low
2/7/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $8.00Low
2/7/2024WedbushLower TargetOutperform ➝ Outperform$14.00 ➝ $13.00Low
2/7/2024HC WainwrightLower TargetBuy ➝ Buy$17.00 ➝ $12.00Low
2/7/2024Jefferies Financial GroupDowngradeBuy ➝ HoldLow
12/21/2023Evercore ISILower TargetOutperform ➝ Outperform$18.00 ➝ $15.00Low
11/29/2023HC WainwrightReiterated RatingBuy ➝ Buy$17.00Low
11/10/2023HC WainwrightLower TargetBuy ➝ Buy$18.00 ➝ $17.00Low
11/10/2023WedbushLower TargetOutperform ➝ Outperform$16.00 ➝ $14.00Low
9/5/2023HC WainwrightReiterated RatingBuy ➝ Buy$18.00Low
9/5/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$16.00Low
8/10/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$17.00 ➝ $18.00Low
7/25/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$16.00Low
6/30/2023HC WainwrightReiterated RatingBuy ➝ Buy$18.00Low
6/26/2023JMP SecuritiesLower Target$26.00 ➝ $16.00Low
4/17/2023HC WainwrightInitiated CoverageBuy$18.00Low
4/10/2023WedbushInitiated CoverageOutperform$17.00Low
2/22/2023JMP SecuritiesReiterated RatingMarket Outperform$29.00Low
12/9/2022JPMorgan Chase & Co.Initiated CoverageOverweight$21.00Low
8/9/2022JMP SecuritiesBoost TargetMarket Outperform$29.00 ➝ $34.00Low
3/16/2022JMP SecuritiesLower TargetMarket Outperform$32.00 ➝ $29.00High
2/22/2022JMP SecuritiesInitiated CoverageOutperform$32.00High
8/23/2021Evercore ISIInitiated CoverageOutperformC$40.00High
8/23/2021Jefferies Financial GroupInitiated CoverageBuy$20.00High
8/23/2021CowenInitiated CoverageOutperformHigh
(Data available from 5/25/2019 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
2/25/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/26/2024
  • 6 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/25/2024

Current Sentiment

  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Rallybio logo
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Read More

Today's Range

Now: $1.56
Low: $1.56
High: $1.65

50 Day Range

MA: $1.76
Low: $1.47
High: $2.98

52 Week Range

Now: $1.56
Low: $1.23
High: $9.14

Volume

180,887 shs

Average Volume

227,256 shs

Market Capitalization

$64.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Rallybio?

The following Wall Street sell-side analysts have issued research reports on Rallybio in the last year: Evercore ISI, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., and Wedbush.
View the latest analyst ratings for RLYB.

What is the current price target for Rallybio?

5 Wall Street analysts have set twelve-month price targets for Rallybio in the last year. Their average twelve-month price target is $12.20, suggesting a possible upside of 682.1%. JPMorgan Chase & Co. has the highest price target set, predicting RLYB will reach $18.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $8.00 for Rallybio in the next year.
View the latest price targets for RLYB.

What is the current consensus analyst rating for Rallybio?

Rallybio currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RLYB.

What other companies compete with Rallybio?

How do I contact Rallybio's investor relations team?

The company's listed phone number is 203-59-3820 and its investor relations email address is [email protected]. The official website for Rallybio is www.rallybio.com. Learn More about contacing Rallybio investor relations.